One year on from the historic approval of the first new Alzheimer’s med in decades, the world’s largest event focused on the disease is set to take place in San 22 July 2022
As the dust settles on this year’s Alzheimer’s Association International Conference (AAIC), the industry is left with a wealth of insight from some of the leadi 13 August 2021
At the Alzheimer’s Association International Conference (AAIC), taking place in Colorado, USA, newly-approved Aduhelm (aducanumab) is understandably the main fo 27 July 2021
Japan’s Eisai has outlined details of 11 presentations slated for the upcoming annual Alzheimer’s Association International Conference (AAIC), taking place from 21 July 2021
Despite a high-profile failure of a drug it was testing with Biogen (Nasdaq: BIIB) earlier this year, Eisai (TYO: 4523) is sticking to its promises not to give 10 May 2019
Japanese pharma major Eisai knows from its own setbacks how challenging R&D in dementia is, but the company is not giving up and is now linking up with a UK cha 8 May 2019
Shares ins Biogen dropped almost 2% on Wednesday morning, despite releasing an upbeat financial results statement which indicated higher-than-expected revenue a 24 April 2019
Just a day after development partner Biogen (Nasdaq: BIIB) revealed the Phase III failure of aducanumab, Japan’s Eisai (TYO: 4523) has announced the start of la 22 March 2019
The most recent new treatment for Alzheimer’s disease was approved by European regulators in May 2002, with the US Food and Drug Administration following suit t 26 July 2017
While researchers have long tangled over the pathology of Alzheimer’s disease, recent trial failures have renewed interest in tau proteins as a therapeutic targ 26 July 2017
The fall of solanezumab late last year, followed by verubecestat in February, sent tremors through the Alzheimer's research community and wiped billions from th 24 July 2017
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.